John SchroyerMarch 13, 2024
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue funding operations and clinical trials, the company announced Wednesday. A psychedelics firm that is still in the pre-revenue stage, the proceeds from the raise will be used to support “certain Phase 3 […]